Ardsley Advisory Partners LP Eli Lilly & CO Transaction History

Ardsley Advisory Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$106.92 - $132.43 $427,680 - $529,720	-4,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$106.79 - $116.16 $480,555 - $522,720	-4,500 Reduced 52.94%	4,000 $447,000
Q2 2019 Aug 13, 2019	BUY	$110.79 - $129.32 $387,765 - $452,620	3,500 Added 70.0%	8,500 $942,000
Q1 2019 May 15, 2019	BUY	$111.31 - $131.02 $556,550 - $655,100	5,000 New	5,000 $649,000
Q1 2018 May 15, 2018	SELL	$74.21 - $87.6 $556,575 - $657,000	-7,500 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$81.94 - $87.89 $614,550 - $659,175	7,500 New	7,500 $634,000
Q3 2017 Nov 14, 2017	SELL	$77.07 - $85.54 $192,674 - $213,850	-2,500 Closed	0 $0
Q2 2017 Sep 21, 2017	BUY	N/A	2,500	2,500 $206,000

3,887

763M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.